Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Barinthus Biotherapeutics (BRNS) Assets Average (2021 - 2026)

Barinthus Biotherapeutics (BRNS) has disclosed Assets Average for 6 consecutive years, with $95.2 million as the latest value for Q1 2026.

  • For Q1 2026, Assets Average fell 37.05% year-over-year to $95.2 million; the TTM value through Mar 2026 reached $95.2 million, down 37.05%, while the annual FY2025 figure was $129.2 million, 31.04% down from the prior year.
  • Assets Average hit $95.2 million in Q1 2026 for Barinthus Biotherapeutics, down from $103.7 million in the prior quarter.
  • Across five years, Assets Average topped out at $285.6 million in Q2 2022 and bottomed at $95.2 million in Q1 2026.
  • Average Assets Average over 5 years is $204.1 million, with a median of $207.0 million recorded in 2024.
  • Year-over-year, Assets Average skyrocketed 161.03% in 2022 and then plummeted 40.58% in 2025.
  • Barinthus Biotherapeutics' Assets Average stood at $272.8 million in 2022, then dropped by 18.55% to $222.2 million in 2023, then fell by 21.48% to $174.5 million in 2024, then crashed by 40.58% to $103.7 million in 2025, then decreased by 8.23% to $95.2 million in 2026.
  • According to Business Quant data, Assets Average over the past three periods came in at $95.2 million, $103.7 million, and $119.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.